Hong Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hong Zhao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Lanjuan Li
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
2 shared publications Er-Mei Chen
Zhejiang University
1 shared publicationGang Wan
1 shared publicationJianhua Hu
A State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine , Zhejiang University , Hangzhou , China
1 shared publicationJianke Ma
B Department of Infectious Diseases , Cixi People's Hospital , Cixi , China
1 shared publicationJifang Sheng
A State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine , Zhejiang University , Hangzhou , China
1 shared publication
Latest Publications
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S131-S132
Clinical and histological features of porto-sinusoidal vascular disorder in drug-induced liver injury population: a retrospective study in biopsy-based cohort
- 20 July 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 78, S131-S132
Clinical and histological features of porto-sinusoidal vascular disorder in drug-induced liver injury population: a retrospective study in biopsy-based cohort
- 18 January 2019
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 13 (3) , 263-269
Upper gastrointestinal hemorrhage in acute-on-chronic liver failure: prevalence, characteristics, and impact on prognosis
Background: Upper gastrointestinal hemorrhage (UGH) is a life-threatening complication in patients with cirrhosis; however, data regarding the role of UGH in acute-on-chronic liver failure (ACLF) are limited. Methods: A prospective, observational cohort study was performed from February 2014 to Mach 2015. Results: UGH was identified in 170 of 492 cirrhotic patients with acute decompensation (AD) at the time of admission. Logistic regression analysis showed that fecal occult blood test positivity was an independent risk factor for UGH in patients with or without ACLF [OR(95%CI): 8.31(4.89–14.10), p<0.001; and 6.29 (1.48–26.76), p=0.031]. Other independent risk factors were a history of gastrointestinal bleeding [OR(95% CI): 13.43 (7.17–25.15), p<0.001], older age [OR(95% CI): 0.98(0.96–0.99), p=0.003], greater INR level [OR(95% CI): 0.48(0.28–0.81), p=0.007] in patients without ACLF. Multivariate Cox proportional hazard model analysis indicated that UGH did not increase mortality at different times in cirrhotic patients with acute decompensation. Conclusions: UGH is a frequent complication in cirrhotic patients with AD, even those with ACLF. Positive fecal occult blood tests and previous GI bleeding were shown to be associated with the risk of UGH. UGH did not significantly increase the risk of mortality in cirrhotic patients with AD or ACLF.
- 18 January 2019
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 13 (3) , 263-269
Upper gastrointestinal hemorrhage in acute-on-chronic liver failure: prevalence, characteristics, and impact on prognosis
Background: Upper gastrointestinal hemorrhage (UGH) is a life-threatening complication in patients with cirrhosis; however, data regarding the role of UGH in acute-on-chronic liver failure (ACLF) are limited. Methods: A prospective, observational cohort study was performed from February 2014 to Mach 2015. Results: UGH was identified in 170 of 492 cirrhotic patients with acute decompensation (AD) at the time of admission. Logistic regression analysis showed that fecal occult blood test positivity was an independent risk factor for UGH in patients with or without ACLF [OR(95%CI): 8.31(4.89–14.10), p<0.001; and 6.29 (1.48–26.76), p=0.031]. Other independent risk factors were a history of gastrointestinal bleeding [OR(95% CI): 13.43 (7.17–25.15), p<0.001], older age [OR(95% CI): 0.98(0.96–0.99), p=0.003], greater INR level [OR(95% CI): 0.48(0.28–0.81), p=0.007] in patients without ACLF. Multivariate Cox proportional hazard model analysis indicated that UGH did not increase mortality at different times in cirrhotic patients with acute decompensation. Conclusions: UGH is a frequent complication in cirrhotic patients with AD, even those with ACLF. Positive fecal occult blood tests and previous GI bleeding were shown to be associated with the risk of UGH. UGH did not significantly increase the risk of mortality in cirrhotic patients with AD or ACLF.
- 1 May 2018
- Published by Springer Nature in Hepatology International
- Vol. 12 (3) , 277-287
Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT
Plasma microRNA (miRNA) levels may be altered during pathological processes; therefore, they may potentially serve as biomarkers for the diagnosis and prognosis of human diseases. This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels.
- 1 May 2018
- Published by Springer Nature in Hepatology International
- Vol. 12 (3) , 277-287
Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT
Plasma microRNA (miRNA) levels may be altered during pathological processes; therefore, they may potentially serve as biomarkers for the diagnosis and prognosis of human diseases. This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels.